Abstract: A method of treating an osmidrosis condition in a subject can include administering a therapeutic agent in an amount that is effective to inhibit expression of an ABCC11 gene in a target cell of the subject to an osmidrosis-reducing level. A therapeutic composition for treating an osmidrosis condition in a subject can include a therapeutically effective amount of an ABCC11 gene-inhibiting agent and a pharmaceutically acceptable carrier.

Abstract: An active agent can be administered transdermally to a patient by using a transdermal patch that has microneedles that are compositionally homogenous with a base layer. The transdermal patch can contain an active agent that can be delivered to a skin surface of a subject when the patch is applied.

Abstract: A therapeutic toxin dosage form for treating a disease, disorder, or condition in a subject can include a microneedle array and a therapeutically effective amount of a therapeutic toxin loaded to the microneedle array for administration to the subject. Additionally, a method of treating a disease, disorder, or condition in a subject can include administering a therapeutically effective amount of a therapeutic toxin to the subject via a microneedle array.

Abstract: A moisture-responsive film can include a complexing substrate and an iodine layer applied to the complexing substrate to form the moisture-responsive film. The moisture-responsive film can include a test area formed on a testing surface of the moisture-responsive film.

Abstract: A method of treating an osmidrosis condition in a subject can include administering a therapeutic agent in an amount that is effective to inhibit expression of an ABCC11 gene in a target cell of the subject to an osmidrosis-reducing level. A therapeutic composition for treating an osmidrosis condition in a subject can include a therapeutically effective amount of an ABCC11 gene-inhibiting agent and a pharmaceutically acceptable carrier.

Abstract: A moisture-responsive film can include a complexing substrate and an iodine layer applied to the complexing substrate to form the moisture-responsive film. The moisture-responsive film can include a test area formed on a testing surface of the moisture-responsive film.

Abstract: The present invention is drawn to a low-cost “meso” device that is able to effectively deliver functional self-delivery siRNA to subject and inhibit expression of a gene in the subject as well as related methods. In particular, a method of transdermally delivering nucleic acid material to a subject is provided. The method includes adapting a motorized meso machine for delivery of nucleic acid material; introducing nucleic acid material into a chamber of the motorized meso machine; and contacting the motorized meso machine to a skin surface of a subject for a period of time sufficient to deliver the nucleic acid material into the skin surface of the subject.

Abstract: A moisture-responsive film can include a complexing substrate and an iodine layer applied to the complexing substrate to form the moisture-responsive film. The moisture-responsive film can include a test area formed on a testing surface of the moisture-responsive film.

Abstract: The present invention is drawn to a low-cost “meso” device that is able to effectively deliver functional self-delivery siRNA to subject and inhibit expression of a gene in the subject as well as related methods. In particular, a method of transdermally delivering nucleic acid material to a subject is provided. The method includes adapting a motorized meso machine for delivery of nucleic acid material; introducing nucleic acid material into a chamber of the motorized meso machine; and contacting the motorized meso machine to a skin surface of a subject for a period of time sufficient to deliver the nucleic acid material into the skin surface of the subject.

Abstract: An active agent can be administered transdermally to a patient by using a transdermal patch that has microneedles that are compositionally homogenous with a base layer. The transdermal patch can contain an active agent that can be delivered to a skin surface of a subject when the patch is applied.

Abstract: The present invention provides for transdermal delivery devices having microneedle arrays, as well as methods for their manufacture and use. In one embodiment, a transdermal delivery device is provided. The transdermal delivery device includes a polymer layer which has microneedles projecting from one of its surfaces. The microneedles are compositionally homogenous with the polymer base layer.

Abstract: The present invention is drawn to formulations for the transdermal delivery of rapamycin or other related compounds. Specifically, in one embodiment a formulation for transdermally delivering rapamycin includes an mTOR inhibitor, such as rapamycin, water, a polymer having surfactant properties, a polymer having thickening properties, a solvent for solubilizing the mTOR inhibitor, a glycol, a C10-C20 fatty acid; and a base.

Abstract: A moisture-responsive film can include a complexing substrate and an iodine layer applied to the complexing substrate to form the moisture-responsive film. The moisture-responsive film can include a test area formed on a testing surface of the moisture-responsive film.

Abstract: The present invention provides for microneedle arrays and related systems and methods. Particularly, microneedle arrays that are configured to deliver active agents, including nucleic acids and vaccines, are provided. Additional related methods of vaccinating and minimizing the amount of vaccine necessary for effective inoculation are also provided.

Abstract: A therapeutic toxin dosage form for treating a disease, disorder, or condition in a subject can include a microneedle array and a therapeutically effective amount of a therapeutic toxin loaded to the microneedle array for administration to the subject. Additionally, a method of treating a disease, disorder, or condition in a subject can include administering a therapeutically effective amount of a therapeutic toxin to the subject via a microneedle array.

Abstract: The present invention provides for microneedle arrays and related systems and methods. Particularly, microneedle arrays that are configured to deliver active agents, including nucleic acids and vaccines, are provided. Additional related methods of vaccinating and minimizing the amount of vaccine necessary for effective inoculation are also provided.

Abstract: Methods of treating pain and/or itch in a targeted region of a subject and compositions and dosage forms therefor are described herein. Such methods can include topically administering a therapeutically effective amount of an mTOR pathway inhibitor to the subject.

Abstract: The present invention is drawn to formulations for the transdermal delivery of rapamycin or other related compounds. Specifically, in one embodiment a formulation for transdermally delivering rapamycin includes an mTOR inhibitor, such as rapamycin, water, a polymer having surfactant properties, a polymer having thickening properties, a solvent for solubilizing the mTOR inhibitor, a glycol, a C10-C20 fatty acid; and a base.

Abstract: The present invention relates to formulations and related methods for transdermal delivery of nucleic acids. Specifically, the invention relates to a formulation containing lipids and an alcohol and which is capable of providing effective transdermal delivery of nucleic acid. The formulation can be used effectively to deliver nucleic acids for gene therapy and the treatment of disease.

Abstract: The invention provides methods, compositions, and kits comprising small interfering RNA (shRNA or siRNA) that are useful for inhibition of viral-mediated gene expression. Small interfering RNAs as described herein can be used in methods of treatment of HCV infection. ShRNA and siRNA constructs targetING the internal ribosome entry site (IRES) sequence of HCV are described.